Nutex Health Inc. NUTX
220.11
15.52
7.59%
as of 25 Sep
- Market cap
- $1.4B
- P/E
- 8.4×
Follow NUTX
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
5.22 | 17.38 | 7.03 | 6.56 |
P/S ratio |
0.71 | 1.20 | 0.75 | 1.39 | |
P/FCF ratio |
3.93 | 4.26 | 2.47 | 4.28 | |
P/Operating CF |
6.96 | 14.88 | 8.80 | 34.33 | |
P/B ratio |
1.58 | 2.47 | 1.50 | 2.31 | |
Price to Tangible BV |
1.72 | 2.70 | 1.63 | 2.48 | |
EV/Sales |
0.86 | 1.33 | 0.87 | 1.50 | |
EV/EBITDA |
2.23 | 3.92 | 2.57 | 3.29 | |
EV/Operating CF |
4.75 | 4.68 | 2.80 | 4.53 | |
EV/FCF |
4.80 | 4.72 | 2.84 | 4.62 | |
Quick Ratio |
3.09 | 3.24 | 3.02 | 4.81 | |
Current Ratio |
3.20 | 3.41 | 3.14 | 5.00 | |
Net Debt/EBITDA |
1.13 | 3.13 | 1.14 | 0.73 | |
Debt/Assets |
33.07% | 32.53% | 32.37% | 31.11% | |
Debt/Equity |
0.73 | 0.71 | 0.70 | 0.59 | |
Asset Turnover |
1.40 | 1.11 | 1.02 | 0.94 | |
Operating CF/Net income |
1.80 | 5.95 | 1.61 | 0.52 | |
Capex/Depreciation |
(0.06) | (0.27) | (0.22) | (0.48) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
9.15% | 10.03% | 4.83% | 9.28% | |
Intangible Assets out of Total Assets |
0.04 | 0.04 | 0.04 | 0.04 | |
Share Based Compensation of Revenue |
4.94% | (1.72%) | (1.81%) | 1.37% | |
Graham Net Nets |
0.10 | 0.04 | 0.10 | 0.11 | |
Graham Number |
170.65 | 119.09 | 138.70 | 208.03 | |
Earnings Yield |
19.16% | 5.75% | 14.23% | 15.24% | |
Free Cash Flow Yield |
25.46% | 23.45% | 40.50% | 23.35% | |
Revenue per Share |
39.96 | 23.84 | 30.97 | 30.67 | |
Operating CF per Share |
14.85 | 11.07 | 10.80 | 4.98 | |
Capex per Share |
(0.05) | (0.22) | (0.17) | (0.37) | |
Free Cash Flow per Share |
14.81 | 10.84 | 10.63 | 4.61 | |
Cash per Share |
24.78 | 29.22 | 30.14 | 30.14 | |
Shareholders Equity per Share |
65.37 | 66.56 | 63.24 | 73.83 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
65.37 | 66.56 | 63.24 | 73.83 | |
Free Cash Flow |
99.21 | 68.98 | 74.32 | 31.66 | |
Working Capital |
407.20 | 380.90 | 395.21 | 468.43 | |
Capital Expenditures |
(0.30) | (1.41) | (1.20) | (2.54) | |
Net Current Asset Value |
66.17 | 43.72 | 64.38 | 128.33 | |
EV/EBIT |
2.35 | 4.21 | 2.76 | 3.48 | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.01 | |
Net Profit Margin |
20.70% | 7.80% | 21.62% | 31.24% | |
Price to Operating Income |
1.93 | 3.80 | 2.40 | 3.22 | |
| Other line items | |||||
Average Receivables |
236.60 | 280.73 | 322.62 | 355.83 | |
Average Payables |
33.11 | 29.69 | 36.17 | 20.01 | |
Average Inventory |
2.71 | 2.86 | 3.90 | 3.24 | |
Average Assets |
701.50 | 786.92 | 859.62 | 902.83 | |
Average Common Equity |
258.91 | 305.99 | 348.66 | 422.09 |
Columns are period end dates